Clinical Trial Update: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating IDE196 (darovasertib) in combination with crizotinib as first-line therapy for metastatic uveal melanoma; the study is act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Crizotinib (Xalkori) (crizotinib)
• Darovasertib (IDE196) (darovasertib)

Snippet

Sponsor: IDEAYA Biosciences | Conditions: Metastatic Uveal Melanoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING